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Abstract
LCRMP-1, a novel isoform of CRMP-1, can promote cancer cell migration, invasion and associate with poor clinical outcome
in patients with non-small-cell lung cancer (NSCLC). However, the underlying regulatory mechanisms of LCRMP-1 in cancer
cell invasiveness still remain obscure. Here, we report that GSK3b can phosphorylate LCRMP-1 at Thr-628 in consensus
sequences and this phosphorylation is crucial for function of LCRMP-1 to promote filopodia formation, migration and
invasion in cancer cells. Impediment of Thr-628 phosphorylation attenuates the stimulatory effects of LCRMP-1 on filopodia
forming, migration and invasion abilities in cancer cells; simultaneously, kinase-dead GSK3b diminishes regulation of
LCRMP-1 on cancer cell invasion. Furthermore, we also found that patients with low-level Ser-9-phosphorylated GSK3b
expression and high-level LCRMP-1 expression have worse overall survival than those with high-level inactive GSK3b
expressions and low-level LCRMP-1 expressions (P,0.0001). Collectively, these results demonstrate that GSK3b-dependent
phosphorylation of LCRMP-1 provides an important mechanism for regulation of LCRMP-1 on cancer cell invasiveness and
clinical outcome.
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Introduction
Metastasis contributes to treatment failure and death in the
majority of cancer patients [1]. The capacity of cancer cells to
progressive metastasis is controlled by complicated cellular pro-
cesses, involving microenvironmental changes, increasing ability of
cell migration or invasion, multiple genetic events and regulatory
factors. Until now, many master inducers and suppressors of
cancer metastasis has been identified to be involved in these
processes, and thus unraveling upstream regulatory pathways of
these proteins may facilitate depicting detailed molecular mech-
anisms for cancer metastasis [2].
Glycogen synthase kinase-3b (GSK3b) is known as a multi-
tasking serine/threonine kinase that control numerous cellular
processes including glycogen metabolism, cell differentiation,
apoptosis, cytoskeleton rearrangement, cell cycle regulation, and
cell proliferation[3,4]. GSK3b regulates a broad range of substrates
through phosphorylation at optimal consensus motifs (Ser/Thr-X-
X-X-Ser/Thr, where X is representative of any amino acid) [3,5].
Usually,most commonsubstrates ofGSK3b need a specificpriming
kinase to increase the efficiency of first phosphorylation at serine or
threonine residues that near to the four residues of GSK3b
phosphorylation site in the carboxyl terminus. For example, casein
kinase 1 prior primes b-catenin to GSK3b phosphorylation [6], and
casein kinase 2 is a priming kinase of glycogen synthase [7].
Collapsin response mediator protein-1 (CRMP-1) suppresses
neuronal growth cone extension during development, and is also
known as a cancer invasion suppressor [8,9]. Recently, we
identified a novel isoform of CRMP-1, the long form CRMP-1
(LCRMP-1) [10]. LCRMP-1 can promote filopodia formation,
cancer cell migration, invasion through functionally against
CRMP-1, and its expression correlates with poor clinical outcome
in non-small-cell lung cancer (NSCLC) patients. LCRMP-1 and
CRMP-1 harbors identical C-terminus sequences from exon-2 to
exon-14; however, N-terminal exon-1 sequence of LCRMP-1 is
distinct with that of CRMP-1 [11]. Among human CRMP family,
amino acid sequence of CRMP-2 is 78% and 76% identity with
CRMP-1 and CRMP-3, respectively [12]. Previously, CRMP-2
has been reported to be phosphorylated by GSK3b at Thr-514,
and associated with impairing neuronal polarization [13]. Notably,
CRMP-1 and CRMP-3 showed highly similar GSK3b phos-
phorylation consensus motifs with CRMP-2 [14]. Consistent
with CRMP-1, LCRMP-1 also contain same motif for GSK3b
phosphorylation.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31689Since LCRMP-1 and CRMP-1 have opposite function on
cancer migration and invasion, whether the function of LCRMP-1
may be regulated by GSK3b should be further studied. In the
present report, we investigate possible regulation of GSK3b on
LCRMP-1. Here, we demonstrated that GSK3b can phosphor-
ylate LCRMP-1 and modulate filopodia formation, cancer cell
migration and invasion. We further confirm the GSK3b-
phosphorylated site in LCRMP-1, investigate its function for cell
invasiveness and evaluate its clinical significant in NSCLC
patients.
Results
GSK3b can phosphorylate LCRMP-1 at Thr-628
To predict whether the classic GSK3b phosphorylation
consensus sequences are existed in LCRMP-1, we first aligned
the protein sequences among CRMP-2, CRMP-1, and LCRMP-1
(Fig. 1A). Previous study showed that Cdk5 is a priming kinase that
phosphorylates CRMP-2 at Ser-522, following with phosphoryla-
tion of CRMP-2 at Thr-514 by GSK3b and resulting in functional
regulation of neuronal polarization [13]. Therefore, we found that
protein sequences of LCRMP-1 contained highly consistent with
Cdk5 and GSK3b phosphorylation motif, thus we speculated that
a major potential phosphorylation site of LCRMP-1 is located at
Thr-628 (Fig. 1A). To examine whether LCRMP-1 can be
phosphorylated by GSK3b, HEK293T cells were cotransfected
with wild-type Flag-tagged LCRMP-1 (WT) in the presence of
empty vector, wild-type GSK3b (WT), constitutively active
GSK3b (CA), or kinase-dead GSK3b (KD). Expression of GSK3b
(CA) was more obviously detected mobility shifts (arrowheads) of
LCRMP-1 (WT) than GSK3b (WT) (Fig. 1B, lane 2 and 3).
However, slow-migration upper bands were completely disap-
peared in cells expressing kinase-deficient form of GSK3b (KD)
(Fig. 1B, lane 4). These results suggest that LCRMP-1 is a
substrate of GSK3b and slowly migrating bands were caused by its
phosphorylation in vivo.
Next, to determine whether GSK3b phosphorylates LCRMP-1
at Thr-628 in vivo, a nonphosphorylated LCRMP-1 mutant was
generated by replacing Thr-628 to Ala (T628A). CL1-0 cells were
cotransfected with LCRMP-1 (WT) or a LCRMP-1 (T628A)
nonphosphorylated mutant in the presence of either empty vector,
GSK3b (CA), or GSK3b (KD). Consistent with previous obser-
vations, GSK3b (CA) and GSK3b (KD) were proved to display
band shift and non-band shift (arrowheads) of LCRMP-1,
respectively (Fig. 1C, lane 2 and 3). Notably, LCRMP-1
(T628A) was resistant to GSK3b (CA) activity and the shifted
bands were almost abolished (Fig. 1C, lane 4). This result was
similar to the conditions of LCRMP-1 (WT) plus GSK3b (KD)
(Fig. 1C, lane 3 and 4), and further confirming that GSK3b indeed
phosphorylated LCRMP-1 at Thr-628 residues. Collectively, all
these results indicated that LCRMP-1 was specifically phosphor-
ylated at Thr-628 by GSK3b in vivo.
Thr-628 phosphorylation of LCRMP-1 is required for
cancer cell invasion, migration and filopodia formation
In our current reports, we have found that wild-type LCRMP-1
enhances filopodia formation, and promotes cell migration and
invasion in noninvasive human lung cancer cell lines [10]. Since
LCRMP-1 can be phosphorylated at Thr-628 by GSK3b, we next
questioned whether the function of LCRMP-1 could be regulated
by this phosphorylation. To address this, we generated a series of
lentivirus that express GFP (control), non-tagged LCRMP-1 (WT),
LCRMP-1 (T628A), or LCRMP-1 (T628D), and transduced them
into low-invasive CL1-0 lung cancer cells which express low level
Figure 1. LCRMP-1 is a substrate of and phosphorylated by
GSK3b at Thr-628. (A) Protein sequence analysis showed the potential
consensus site of LCRMP-1 for the phosphorylation by GSK3b. Protein
sequences are aligned among CRMP2, CRMP-1, and LCRMP-1. The
numbers represent amino acid sites and underline shows a potential
phosphorylation site for Cdk5. (B) GSK3b phosphorylates LCRMP-1 (WT)
in vivo. HEK293Tcellswere co-transfectedwith Flag-taggedLCRMP-1 and
distinct activity of Flag-tagged GSK3b (WT, CA and KD form). Equal
amount of plasmids were transfected into every condition by using
empty vectors. Cells were lysed 30 hr post-transfection and protein
extracts were analyzed by immunoblotting with anti-Flag antibodies. (C)
GSK3b phosphorylates LCRMP-1 (WT) at Thr-628 in vivo. CL1-0 cells were
co-transfected either Flag-tagged LCRMP-1(WT) or LCRMP-1 (T628A,
T628D) mutants in the presence or absence of distinct activity of Flag-
tagged GSK3b (CA and KD form). Empty vectors were used for
supplement to equal amount of plasmids in transfection assay. Cell
lysates were harvested 48 hr post-transfection and analyzed by
immunoblotting with anti-Flag and anti-b-actin antibodies.
doi:10.1371/journal.pone.0031689.g001
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31689of endogenous LCRMP-1 [11]. Protein expression of wild-type or
mutant LCRMP-1 was confirmed by immunoblotting analysis
using anti-LCRMP-1 antibodies (Fig. 2A). These cells were then
used to examine the ability of cell invasion. As expected, LCRMP-
1 (WT) overexpression contributed to an increased cell invasive-
ness compared with GFP control (Fig. 2B). However, T628A
nonphosphorylated mutant of LCRMP-1 was greatly diminished
cell invasiveness (Fig. 2B). Conversely, phospho-mimic LCRMP-1
(T628D), which was expected to mimic the phosphorylated form,
displayed enhanced invasion ability similar to wild-type LCRMP-1
(WT). To further explore the effect of Thr-628 phosphorylation of
LCRMP-1 expression on CL1-0 cell motility, we performed video
time-lapse microscopy assay to monitor moving tracks of at least
10 individual cells over a 20-hour period. Lentivirus-transduced
CL1-0 cells expressing GFP-LCRMP-1 (WT) or GFP-LCRMP-1
(T628D) increased both migration distance and migration velocity
compared to GFP vector (Fig. 2C, D, and E). However, GFP-
LCRMP-1 (T628A) showed marked compression of distance and
velocity of migration (Fig. 2C, D, and E). These results suggested
that phosphorylation of LCRMP-1 at Thr-628 is a prerequisite for
cell invasiveness and cell migration.
Next, we further examined the effects of GSK3b on LCRMP-1
induced filopodia formation. CL1-0 cells were transiently trans-
fected with GFP control, GFP-LCRMP-1 (WT), GFP-LCRMP-1
(T628A), or GFP-LCRMP-1 (T628D) and following by staining
with actin using rhodamine-conjugated phalloidin. Consistent with
our current reports, immunofluorescence analysis revealed that
numbers of filopodia that induced by ectopic expression GFP-
LCRMP-1 (WT) in CL1-0 cells were more than that by GFP
vector control. Conversely, numbers of filopodia formation were
obviously attenuated in cells expressing nonphosphorylated
mutant GFP-LCRMP-1 (T628A) (Fig. 3A; 3B, p,0.0001). In ad-
dition, GFP-LCRMP-1 (T628D) was also induced more filopodia
that similar to GFP-LCRMP-1 (WT), (Fig. 3A; 3B, p,0.0001).
These data indicated that phosphorylation of LCRMP-1 at Thr-
628 is crucial for filopodia formation.
GSK3b phosphorylates LCRMP-1 and modulates cancer
cell invasion
To further detect the effects of GSK3b on LCRMP-1(WT)-
induced cancer cell invasion, lentivirus expressing GFP control,
GSK3b (WT),GSK3b (CA), orGSK3b (KD) wereinfected inCL1-
0/LCRMP-1 overexpression cells (lines 1015 and 1003) which have
been previously shown to strongly induce cell invasiveness [10].
Consistent with our previous findings (Fig. 1B and C), immuno-
blotting analysis showed that GSK3b (CA) induced LCRMP-1 with
shifted band compared to GFP control (Fig. 4A, lane 1 and 3; lane 5
and 7), but a non-shifted band was observed in GSK3b (KD)
(Fig.4A,lane 4 and lane 8).Based onaboveconditions, the results of
invasion assay were also shown that GSK3b (CA)-introduced CL1-
0/LCRMP-1 cells (1015) could further promote cell invasion
compared to control cells (Fig. 4B). However, GSK3b (KD)-
introduced cells resulted in a decreased in invasion ability (Fig. 4B).
Taken together, these results demonstrated that GSK3b could
modulate LCRMP-1 activity through a phosphorylation-dependent
manner to control cancer cell invasion.
Low expression of inactive GSK3b and high expression of
LCRMP-1 correlate with poor overall survival in NSCLC
patients
Although our results consistently suggested that function of
LCRMP-1 could be regulated by GSK3b phosphorylation, such
studies do not fully reflect clinical malignancy. Accordingly, we
extended our analysis by examining inactive form GSK3b and
LCRMP-1 protein expression levels in tumor specimens from 142
NSCLC patients. The clinical characteristics of these patients are
summarized in Table 1. Serial sections of each specimen were
stained with antibodies against LCRMP-1 and Ser-9-phosphory-
lated GSK3b that indicated the status of inactive form GSK3b due
to the Akt-mediated activation which results in suppression of
GSK3b activity through phosphorylation at Ser-9 [15]. Our
results showed typical staining of LCRMP-1 and Ser-9-phosphor-
ylated GSK3b in patient’s specimen (Fig. 5A). Consistent with our
previous reports, high-level LCRMP-1 had significantly poor
overall survival compared with low-level LCRMP-1 in patients
with NSCLC [10,11]. Notably, analysis of the combined effect of
both proteins on patients’ prognoses revealed that patients with
low-level expression of inactive form GSK3b and high-level
expression of LCRMP-1 had poorer overall survival than those
with high-level inactive form GSK3b expression and low-level
LCRMP-1 expression (Fig. 5B, p,0.00001). Multivariable Cox
proportional-hazards regression analyses, with a stepwise selection
model, were present to evaluate the associations of various
independent prognostic factors with patient survival (Table 2).
These results suggest that high activity GSK3b and high-level
LCRMP-1, possibly mimicking the phosphorylated status of
LCRMP-1, are associated with increasing cancer invasiveness
and poorer overall survival.
Discussion
Our study primarily investigated the regulatory mechanism of
post-translation modification associated with the cancer cell
migration and invasiveness of LCRMP-1. Here, we showed that
GSK3b-dependent phosphorylation of LCRMP-1 positively
regulates filopodia formation, migration and cancer cell invasion.
On the basis of GSK3b-phosphorylated consensus motifs, Thr-628
amino acid residue of LCRMP-1 is the master phosphorylation
site for GSK3b (Fig. 1). A substitution of Thr-628 for Ala in
LCRMP-1 led to impair filopodia formation, migration and
cancer cell invasion, whereas a replacement of Thr-628 to Asp
greatly restored its function (Fig. 2 and 3). Consistent with these
observations, ectopic expression of kinase-dead GSK3b dimin-
ished LCRMP-1-induced invasive ability (Fig. 4). Moreover,
clinical NSCLC patients with low-level of inactive GSK3b and
high-level LCRMP-1 protein expression is associated with poor
overall survival than those with high-level inactive form GSK3b
expression and low-level LCRMP-1 expression (Fig. 5B). Thus,
our results provide evidence to support the crucial mechanism of
GSK3b-dependent phosphorylation to control the LCRMP-1-
mediated filopodia formation, migration and invasive abilities in
cancer cells.
Sequence analysis indicated that there has a Cdk5 (priming
kinase) phosphorylation site in both LCRMP-1 and CRMP-1
(Fig. 1A). After phosphorylation at Ser-636 by Cdk5, GSK3b in
turn phosphorylates Ser-632 and Thr-628 sequentially. There-
fore, GSK3b may induce slower migrating bands in LCRMP-1
including both Ser-632 and Thr-628 phosphorylation in cells,
and the bands induced by constitutively active GSK3b were more
active than that of wild-type GSK3b (Fig. 1B). In detailed
analysis, we found that LCRMP-1 mutant, T628A, could block
most of GSK3b phosphorylation induced migrating bands
(Fig. 1C). This may indicate that Thr-628 of LCRMP-1 may
be the dominant and important phosphorylation site for GSK3b
phosphorylation. However, we could not exclude the possibility
that constitutively active GSK3b can phosphorylate other sites of
LCRMP-1.
LCRMP-1 and GSK3b in Lung Cancer
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31689Figure 2. Phosphorylation of LCRMP-1 at Thr-628 is critical for cancer invasion and migration. (A) Protein expression levels of exogenous
untagged LCRMP-1 (WT), LCRMP-1 (T628A), and LCRMP-1 (T628D) are confirmed by immunoblotting. After 48 hours post lentivirus infection, CL1-0
cells were stably expressing wild-type and mutant LCRMP-1. Lentivirus expressing GFP served as control. Cell lysates were harvested, following by
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the extracellular matrix including actin polymerization and filopodia
formation [16]. Our findings reveal that blockage of GSK3b-
mediated phosphorylation of LCRMP-1 at Thr-628 leads to a
regression of filopodia formation. A previous report was described
that GSK-3 phosphorylation for Paxillin is necessary for cytoskeletal
rearrangement [17]. Thus, we speculate that GSK3b may positively
promote regulation of actin cytoskeleton and tumor invasion. In
contrast to positively role, GSK3b is also reported to perform its
suppressive roles for its substrates [18]. GSK3b phosphorylation for
some nuclear transcription factors, such as b-catenin and Snail,
trigger proteasomal degradation, following with suppression on
epithelial–mesenchymal transition (EMT) and tumor invasion
[6,19–21]. GSK3b simultaneously localizes in cytoplasm and
nucleus [22], as consistent with our results of immunohistochemical
staining (Fig. 5A), and LCRMP-1 is a stable cytosolic protein [10].
Therefore, GSK3b govern cell invasion is possibly dependent on the
characterization of its protein substrates. High-level LCRMP-1
expression is associated with poor overall and disease-free survival
compared to low expression group in NSCLC patients [10,11].
Thus, LCRMP-1 potentially serves as a best candidate to identify
high-risk patients. In this study, we showed a very interesting finding
that patients with low-level phosphorylated GSK3b and high-level
LCRMP-1 expressions had worse overall survival than the other
catalog groups. Focusing on the low-level LCRMP-1 expression or
the high-level LCRMP-1 expression group, we could also found that
high-level of phosphorylated GSK3b expression may discriminate
better outcome from low-level phosphorylated GSK3b expression,
respectively. The combined effects of inactive form GSK3b and
LCRMP-1 protein expression may have important clinical implica-
tions to indicate the high-risk subset of NSCLC patients as
candidates for additional effective adjuvant therapy. The results
suggestthatGSK3bphosphorylationofLCRMP-1isassociatedwith
poor clinical outcome. However, there still have some limitations in
our experiments. Although the reference indicated that Ser-9-
phosphorylated GSK3b can indicate the status of inactive form
GSK3b due to the Akt-mediated activation which results in
suppression of GSK3b activity through phosphorylation at Ser-9
[15], whether Ser-9 phosphorylation of GSK3b inhibits its ability to
phosphorylate LCRMP-1 is still not clear. To solve this problem,
generating a specific anti-phospho-Thr-628 LCRMP-1 antibody for
immunohistochemistry should be the most important issues in the
future. This may confirm the clinical significance of GSK3b induced
phosphorylation of LCRMP-1 in NSCLC patients.
In addition, we also found that patients with low-levels (n=73)
or high-levels (n=69) of Ser-9-phosphorylated GSK3b expression
were almost equal in distribution. Cells exist at different actual
levels of active GSK3b unless distinct signaling pathways for
inhibiting GSK3b are triggered concurrently, such as MAPK and
phosphatidylinositol-3-OH kinase/Akt pathways [20]. Thus, we
speculate that distinct activated extent of signaling pathways to
induce an inhibition of GSK3b activity may lead to different
outcome for patients with LCRMP-1 expression. Therefore,
further investigating upstream signaling pathway for regulation
of GSK3b may provide a better diagnosis for NSCLC patients
with low-levels or high-levels of LCRMP-1 expression.
In conclusion, we show a new regulatory mechanism for
GSK3b to phosphorylate an invasion enhancer LCRMP-1 and
thus could further fine-tune cancer cell invasion abilities.
Additionally, LCRMP-1 expression and Ser-9-phosphorylated
GSK3b levels may have clinical implications in the outcome
prediction of patients with NSCLC.
Materials and Methods
Ethics statement
This investigation was approved by the Institutional Review
Board of the National Taiwan University Hospital and obtained
informed written consent statement from all participant patients
involved in our study.
Patients and Tumor Specimens
Lung tumor tissue specimens were obtained from patients
(n=142) with histologically confirmed NSCLC who had under-
gone complete surgical resections at the National Taiwan
University Hospital (Taipei, Taiwan) between December 28,
1995, and December 26, 2005. This investigation was approved
by the Institutional Review Board of the National Taiwan Uni-
versity Hospital. The enrolled patients had not been treated with
neoadjuvant chemotherapy or irradiation therapy. All specimens
were formalin fixed, sectioned, stained with hematoxylin and
eosin, and examined by microscopy. Pathological staging was
performed by Dr. Yih-Leong Chang (Department of Pathology
and Graduate Institute of Pathology, National Taiwan University)
according to the international staging system for lung cancer [23].
Immunohistochemical analysis
Immunohistochemical staining of tumor tissue samples from
patients with NSCLC was carried out as previously described [11].
In brief, the sections for analysis of LCRMP-1 or phosphorylated
GSK3b protein expression were first autoclaved in Trilogy
Solution (Cell Marque Corp., Rocklin, CA.) or Antigen Retrieval
Citra Solution (Biogenex, San Ramon, CA) at 121uC for
10 minutes. The samples were subsequently made a treatment of
3% H2O2-methanol, incubation with DakoCytomation Dual
EndogenousEnzyme Block (DakoCytomation, Inc., Carpinteria,
CA) for 10 minutes, Ultra V Block (Lab Vision Corporation,
Fremont, CA) for 10 minutes, antibody-dilution buffer (Ventana
Medical Systems, Inc., Tucson, AZ) for 10 minutes, and finally
with a phosphorylated GSK3b (Cell signaling, Danvers, MA)
antibody for 6 hours at room temperature or a polyclonal anti–
LCRMP-1 antibody (C2; 1:300 dilution) overnight at 4uC.
Detection of the immunostaining was determined using Super
Sensitive Non-Biotin Polymer HRP Detection System (BioGenex,
San Ramon, CA) according to the manufacturer’s protocol.
Modified Boyden chamber invasion assay
Modified Boyden chambers with polycarbonate-membrane
inserts (pore size 8 mm; Falcon, Becton Dickinson) coated with
30 mg Matrigel (BD) were performed cell invasion assays. 2.5610
4
cells suspended in RPMI medium containing 10% NuSerum
assessing with immunoblotting using anti-LCRMP-1 antibody and anti-b-actin antibodies. (B) Nonphosphorylated LCRMP-1 (T628A) mutant lowers
activity of cell invasion. The invasive capacity of these cells was determined with the modified Boyden chambers invasion assay in vitro. Percentage of
invasive ability was normalized to GFP control. Data were shown as means 6 SEM for three-independent experiments (n=3). (C) Nonphosphorylated
LCRMP-1 (T628A) mutant greatly suppressed cell migration tracks. Tract plots showed CL1-0 cells expressing GFP, GFP-LCRMP-1 (WT), GFP-LCRMP-1
(T628A), GFP-LCRMP-1 (T628D), respectively. Moving tracks of at least 10 representative cells at the start point all set to ‘0,0’ over a 20-hour period
(different lines) showed the representative motility of cells. Scale bar, 100 mm. (D, E) Total migration distance (D) and cell migration velocity (E) were
quantified from cell tracking assay for 20 hours. Data were presented as means 6 SEM.
doi:10.1371/journal.pone.0031689.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31689Figure 3. Phosphorylation of LCRMP-1 at Thr-628 is required for filopodia formation. (A) Nonphosphorylated LCRMP-1 (T628A) mutant
impairs filopodia formation. CL1-0 cells were transiently transfected with GFP-tagged LCRMP-1 (WT), LCRMP-1 (T628A), and LCRMP-1 (T628D). At
24 hours after transfection, these cells were fixed, permeabilized and then immunostained with rhodamine-conjugated phalloidin (red) for actin and
DAPI (blue) for visualizing nuclei. Representative immunofluorescence images were visualized using fluorescence microscope. Scale bar, 10 mm. Insets
show higher magnifications (4006). (B) Numbers of filopodia were counted with at least six cells per group. Data were presented as means 6 SEM.
doi:10.1371/journal.pone.0031689.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31689Figure 4. GSK3b modulates ability of LCRMP-1-induced cancer cell invasion. (A) Lentivirus expressed GFP control, myc-tagged GSK3b (WT),
GSK3b (CA), or GSK3b (KD) in CL1-0/LCRMP-1 (WT) overexpression cells (1015 and 1003). After 48 hours postinfection, these cells were lysed and
subjected to immunoblotting analysis with using anti-Flag, anti-Myc, and anti-b-actin antibodies. (B) GSK3b activity affects LCRMP-1-induced cancer
cell invasion. CL1-0/LCRMP-1 overexpression cells (1015) were infected with lentivirus expressing GFP control, myc-tagged GSK3b (CA) or GSK3b (KD).
After 48 hours postinfection, these cells were subjected to the modified Boyden chambers invasion assay in vitro. Normalization to GFP control
served as percentage of invasive ability.
doi:10.1371/journal.pone.0031689.g004
Table 1. LCRMP-1 and phosphorylated GSK3b expression in relation to clinical parameters and pathological characteristics*.
LCRMP-1 p-GSK3b
Category Subcategory Number #50% (%) .50% (%) P #70% (%) .70% (%) P
Total patients 142 102 (71.8) 40 (28.2) 73 (51.4) 69 (48.6)
Sex Female 78 55 (53.9) 23 (57.5) 0.7 44 (60.3) 34 (49.3) 0.188
Male 64 47 (46.1) 17 (42.5) 29 (39.7) 35 (50.7)
Histological type{ Adenocarcinoma 123 86 (87.8) 37 (94.9) 0.215 60 (85.7) 63 (94.0) 0.108
Squamous cell carcinoma 14 12 (12.2) 2 (5.1) 10 (14.3) 4 (6.0)
Tumor size, cm .3 74 57 (55.9) 17 (42.5) 0.151 41 (56.2) 33 (47.8) 0.32
#3 68 45 (44.1) 23 (57.5) 32 (43.8) 36 (52.2)
Vascular invasion Positive 25 19 (18.6) 6 (15.0) 0.61 14 (19.2) 11 (15.9) 0.613
Negative 117 83 (81.4) 34 (85.0) 59 (80.8) 58 (84.1)
Lymph node metastasis Positive 32 18 (17.7) 14 (35.0) 0.026 18 (24.7) 14 (20.3) 0.534
Negative 110 84 (82.4) 26 (65.0) 55 (75.3) 55 (79.7)
Extranodal extension Positive 20 10 (9.8) 10 (25.0) 0.019 11 (15.1) 9 (13.0) 0.729
Negative 122 92 (90.2) 30 (75.0) 62 (84.9) 60 (87.0)
Tumor stage Stage I 107 82 (80.4) 25 (62.5) 53 (72.6) 54 (78.3)
Stage II 17 13 (12.8) 4 (10.0) 11 (15.1) 6 (8.7)
Stage III–IV 18 7 (6.9) 11 (27.5) 0.004 9 (12.3) 9 (13.0) 0.505
LCRMP-1 expression, % .50 102 – – – 56 (76.7) 46 (66.7) 0.184
#50 40 – – 17 (23.3) 23 (33.3)
p-GSK3b expression, % .70 69 46 (45.1) 23 (57.5) 0.184 – – –
#70 73 56 (54.9) 17 (42.5) – –
*P values were calculated using a two-sided chi-squared test. Abbreviations: LCRMP-1, long-form collapsin response mediator protein-1; p-GSK3b, phosphorylated
Glycogen synthase kinase-3b.
{Adenosquamous carcinomas are not included.
doi:10.1371/journal.pone.0031689.t001
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1 ml medium was added to cover the lower chambers. After
24 hours incubation at 37uC, cells were fixed with methanol at
room temperature for 10 minutes. After fixation, samples were
stained with a 50 mg/ml solution of propidium iodide (Sigma, St.
Louis, MO) at room temperature for 30 minutes. Each membrane
was photographed and counted the number of cells under a
microscope at a magnification of 650, using the Analytical
Imaging Station software package (Imaging Research Inc., St.
Catharines, ON, Canada). Each experiment was assayed in
triplicate.
Immunofluorescence staining for observation of
filopodia formation
Transfected or lentivirus-infected cells were fixed with 3.7%
cold paraformaldehyde, washed with PBS, following by permea-
bilizing with 0.1% Triton X-100. The cells were then stained with
rhodamine-conjugated phalloidin (red, Molecular Probes, Eugene,
OR). The cells were mounted onto microscope slides with
ProLongH Gold antifade reagent with DAPI (Molecular Probes)
and then examined and photographed using LSM 700 laser
scanning confocal microscope from Carl Zeiss.
Cell migration analysis
Moving tracks of migrating cells were performed by video time-
lapse microscopy as previously described [24]. In brief, cells were
maintained in growth medium at 37uC/5% CO2 and time-lapse
images were observed under a AF 6000 LX microscope (Meyer
Instruments,Inc.) for the time period of 20 hours. Images were
taken with a CoolSNAP HQ CCD camera (Roper Scientific, NJ)
at 5-minute intervals and processed by MetaMorph 5.0 software
(Universal Imaging, Downingtown, PA).
Cell culture and transfection
The human lung adenocarcinoma cell lines (CL1-0 cells) were
isolated from a 64-year-old male patient with a poorly differen-
Table 2. Hazard ratios for death (from any cause) among
patients with NSCLC, according to multivariable Cox
regression analysis*.
Variable Hazard ratio (95% C.I.) P
LCRMP-1 26.22 (7.56 to 90.94) ,.0001
p-GSK3b 0.48 (0.2 to 1.16) 0.102
Sex 2.48 (0.97 to 6.37) 0.058
Histological type 0.15 (0.04 to 0.52) 0.003
Tumor stage 0.47 (0.3 to 0.73) 0.001
*Stepwise selection was used to choose the optimal multivariable Cox
proportional hazard regression model. LCRMP-1 and phosphorylated GSK3b
expression was designated as ‘high’ or ‘low’ using 50% and 70% cell positivity
as the cut-off point respectively, and were adjusted by histological type
(squamous cell carcinoma as the referent vs. adenocarcinoma), and stage (stage
I as the referent vs. stage II vs. stage III). P values (two-sided) were calculated
using a chi-square test. Abbreviations, LCRMP-1, long-form collapsin response
mediator protein-1; p-GSK3b, phosphorylated Glycogen synthase kinase-3b;C I ,
confidence interval.
doi:10.1371/journal.pone.0031689.t002
Figure 5. Kaplan-Meier survival plots for NSCLC patients grouped by phosphorylated GSK3b and LCRMP-1 protein expression
levels. (A) Typical protein expression patterns of phosphorylated GSK3b and LCRMP-1 were detected by immunohistochemistry using anti-phospho-
GSK3b (Ser9) and anti-LCRMP-1 antibodies (C2) in serial dissections of primary tumor specimens from 142 NSCLC patients who underwent surgical
resections. Results are shown + and 2 denotes tumors with and without over-expression with indicated protein respectively. Scale bars, 100 mm.









+. P values were performed by 2-sided log-rank tests.
doi:10.1371/journal.pone.0031689.g005
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Transwell invasion to get 5 sublines with progressive invasiveness,
with similar genotypic background (designated CL1-1, CL1-2,
CL1-3, CL1-4, and CL1-5) as previously described [25].
HEK293T cell lines were purchased from American Type Culture
Collection (ATCC, USA). The CL1-0 and HEK293T cells were
grown in RPMI and DMEM medium containing 10% FBS and
2 mM L-glutamine (all from Invitrogen, Eugene, OR) at 37uCi na
humidified atmosphere of 5% CO2-95% air, respectively. All cell
lines in this study were tested with mycoplasma-free condition. All
transfection experiments were carried out using Lipofectamine or
Lipofectamine 2000 reagents (Invitrogen) according to the
manufacturer’s instructions.
Protein sequences alignment and Plasmids
Amino acid sequences alignment of CRMP-2, CRMP-1, and
LCRMP-1 are based on their Gene bank accession number
NP_001377, NP_001304, and NP_001014809, respectively. The
LCRMP-1 expression plasmid pCMV-Tag2A-LCRMP-1(WT)
and pEGFP-LCRMP-1(WT) were described as previously [10].
Amino-acid substitution mutants of LCRMP-1 were generated by
PCR-based site-directed mutagenesis with a QuikChange kit
(Stratagene, Santa Clara, CA) and verified by DNA sequencing.
FLAG-tagged GSK3b (WT, CA and KD form) expression
plasmids were subcloned from pCMV-5A-GSK3b (WT, CA and
KD form, a gift from M.-C. Hung) into pFLAG -CMV-5a vector
(Sigma).
Antibodies
Primary antibodies for immunoblotting were as follows:
monoclonal anti-Flag (M2; Sigma), anti-Myc (9E11; Millipore,
Billerica, MA), anti-b-actin (Sigma) and polyclonal anti-LCRMP-1
antibody. The HRP conjugated goat anti-mouse and goat anti-
rabbit secondary antibodies were purchased from (Amersham
Biosciences, Pittsburgh, PA).
Lentivirus production and transduction
GFP-tagged, untagged LCRMP-1 (WT, T628A and T628D),
and myc-tagged GSK3b (WT, CA and KD form) were
constructed by cloning their cDNA into pTYEF lentiviral vector.
Briefly, HEK293T cells were contransfected with the indicated
lentiviral vector and three helper plasmids pHP-dl-N/A, pHEF-
VSVG, and pCEP4-Tat by using Lipofectamine 2000 reagents
according to manufacturer’s protocols. Virus-containing medium
was collected at 24, 48, 72 hours post-transfection, centrifuged,
and filtered through 0.45 mm-pore-size filters. The percentage of
pTYEF-GFP-infected cells by flow cytometry were determined the
relative lentivirus titers. Cells were infected with GFP or the
indicated lentivirus in media containing polybrene (8 mg/ml).
After twenty-four hours post-infection, cells were treated with fresh
medium for 24–48 hours and then used for all experiments.
Cell lysate preparation and immunoblotting
All experiments were performed according to standard
protocols. Briefly, preparation of whole-cell lysates for immuno-
blotting and immunoprecipitation were using IP lysis buffer
(20 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40,
100 mMN a 3VO4, 50 mM NaF, 30 mM sodium pyrophosphate)
containing protease inhibitors (protease inhibitor cocktail; Roche
Diagnostics, Basel, Switzerland). After brief sonication and
centrifugation, protein samples were resolved by SDS-PAGE gels,
transferred into PVDF membranes (Millipore), blotted with the
indicated antibodies and finally detected chemiluminescent signals
using X-ray films.
Statistical analysis
Data are shown as Mean 6 SEM. and statistical analyses were
performed by Student’s t-test or Pearson’s x2 test. The overall
survivals for patient groups with different expression signatures
were determined using SPSS software (v10.0; SPSS, Inc., Chicago,
IL) by the Kaplan–Meier method and two-sided log-rank tests.
Immunoreactivity in more than 50% and 70% of the tumor
specimens was defined to high level of LCRMP-1 and phosphor-
ylated GSK3b expression, respectively. P values,0.05 were
considered to be statistically significant.
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